Cargando…
Efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia: a phase 2, randomized, double-blind, placebo-controlled trial
BACKGROUND: Many patients who recovered from COVID are still suffering from pulmonary dysfunction that can be persistent even for months after infection. Therefore, treatment to prevent irreversible impairment of lung function is needed. Treamid (bisamide derivative of dicarboxylic acid, BDDA) was s...
Autores principales: | Bazdyrev, Evgeny, Panova, Maria, Brachs, Maria, Smolyarchuk, Elena, Tsygankova, Daria, Gofman, Liudmila, Abdyusheva, Yana, Novikov, Fedor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632561/ https://www.ncbi.nlm.nih.gov/pubmed/36329513 http://dx.doi.org/10.1186/s12967-022-03660-9 |
Ejemplares similares
-
Antifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis
por: Skurikhin, Evgenii, et al.
Publicado: (2020) -
The Hidden Pandemic of COVID-19-Induced Organizing Pneumonia
por: Bazdyrev, Evgeny, et al.
Publicado: (2022) -
Lung Fibrosis after COVID-19: Treatment Prospects
por: Bazdyrev, Evgeny, et al.
Publicado: (2021) -
Imidazole-4-N-acetamide Derivatives as a Novel Scaffold for Selective Targeting of Cyclin Dependent Kinases
por: Rusina, Polina, et al.
Publicado: (2023) -
Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study
por: Tkachuk, Artem P., et al.
Publicado: (2020)